{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:46:08Z","timestamp":1790333168602,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001798","name":"Edith Cowan University PhD Scholarship","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001798","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011719","name":"Cancer Research Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011719","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001170","name":"Cancer Council Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001170","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australia New Zealand Gynaecological Oncology Group"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.canlet.2019.10.014","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T20:04:08Z","timestamp":1570824248000},"page":"59-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":170,"special_numbering":"C","title":["Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?"],"prefix":"10.1016","volume":"468","author":[{"given":"Du-Bois","family":"Asante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Calapre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Ziman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek M.","family":"Meniawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8613-3570","authenticated-orcid":false,"given":"Elin S.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.canlet.2019.10.014_bib1","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA A Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.canlet.2019.10.014_bib2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5694\/mja14.00132","article-title":"Survival of Australian women with invasive epithelial ovarian cancer: a population\u2010based study","volume":"201","author":"Anuradha","year":"2014","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.canlet.2019.10.014_bib3","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","article-title":"Carcinoma of the ovary","volume":"95","author":"Heintz","year":"2006","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"6","key":"10.1016\/j.canlet.2019.10.014_bib4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/jama.2017.21421","article-title":"Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force","volume":"319","author":"Henderson","year":"2018","journal-title":"Jama"},{"issue":"24","key":"10.1016\/j.canlet.2019.10.014_bib5","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2007.14.3065","article-title":"New technologies for human cancer imaging","volume":"26","author":"Frangioni","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2019.10.014_bib6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/IGC.0000000000000586","article-title":"Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers","volume":"26","author":"S\u00f6l\u00e9tormos","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2019.10.014_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ajog.2008.04.009","article-title":"The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?","volume":"199","author":"Nossov","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1183\/09031936.00094206","article-title":"Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax","volume":"31","author":"Bagan","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.canlet.2019.10.014_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/172460089801300402","article-title":"CA 125: the past and the future","volume":"13","author":"Bast","year":"1998","journal-title":"Int. J. Biol. Mark."},{"key":"10.1016\/j.canlet.2019.10.014_bib11","first-page":"1","article-title":"Liquid biopsy and minimal residual disease\u2014latest advances and implications for cure","author":"Pantel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.canlet.2019.10.014_bib12","first-page":"3363","article-title":"The added value of circulating tumor cells examination in ovarian cancer staging","volume":"5","author":"Kolostova","year":"2015","journal-title":"Am. J. Canc. Res."},{"issue":"5","key":"10.1016\/j.canlet.2019.10.014_bib13","first-page":"973","article-title":"Molecular characterization of circulating tumor cells in ovarian cancer","volume":"6","author":"Kolostova","year":"2016","journal-title":"Am. J. Canc. Res."},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib14","doi-asserted-by":"crossref","first-page":"812","DOI":"10.18632\/oncotarget.22549","article-title":"Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells","volume":"9","author":"Obermayr","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.canlet.2019.10.014_bib15","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.18632\/oncotarget.23943","article-title":"Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer","volume":"9","author":"Guo","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.canlet.2019.10.014_bib16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ygyno.2017.02.042","article-title":"Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer","volume":"145","author":"Lee","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"44","key":"10.1016\/j.canlet.2019.10.014_bib17","doi-asserted-by":"crossref","first-page":"77195","DOI":"10.18632\/oncotarget.20428","article-title":"Circulating tumor cells in the differential diagnosis of adnexal masses","volume":"8","author":"Suh","year":"2017","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.canlet.2019.10.014_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015354","article-title":"Post-debulking circulating tumor cell as a poor prognostic marker in advanced stage ovarian cancer: a prospective observational study","volume":"98","author":"Kim","year":"2019","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2012.09.021","article-title":"Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance\u2014a study of the OVCAD consortium","volume":"128","author":"Obermayr","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"63","key":"10.1016\/j.canlet.2019.10.014_bib20","doi-asserted-by":"crossref","first-page":"106415","DOI":"10.18632\/oncotarget.22468","article-title":"Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium","volume":"8","author":"Obermayr","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2011.06.022","article-title":"Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study","volume":"123","author":"Behbakht","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2019.10.014_bib22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2011.05.028","article-title":"Circulating tumor cells predict progression free survival and overall survival in patients with relapsed\/recurrent advanced ovarian cancer","volume":"122","author":"Poveda","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2019.10.014_bib23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ygyno.2013.08.006","article-title":"Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients","volume":"131","author":"Liu","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2019.10.014_bib24","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1159\/000492521","article-title":"Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker","volume":"48","author":"Zhang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"3","key":"10.1016\/j.canlet.2019.10.014_bib25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ygyno.2014.06.013","article-title":"Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer","volume":"134","author":"Pearl","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2019.10.014_bib26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2015.03.002","article-title":"Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs)","volume":"137","author":"Pearl","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"16","key":"10.1016\/j.canlet.2019.10.014_bib27","doi-asserted-by":"crossref","first-page":"14055","DOI":"10.1021\/acsami.8b02583","article-title":"Folic acid targeting for efficient isolation and detection of ovarian cancer CTCs from human whole blood based on two-step binding strategy","volume":"10","author":"Nie","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1039\/C5BM00207A","article-title":"Folic acid conjugated magnetic iron oxide nanoparticles for nondestructive separation and detection of ovarian cancer cells from whole blood","volume":"4","author":"Liu","year":"2016","journal-title":"Biomater. Sci."},{"issue":"3","key":"10.1016\/j.canlet.2019.10.014_bib29","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3892\/or.2016.4926","article-title":"Analysis of the gene expression profile in response to human epididymis protein 4 in epithelial ovarian cancer cells","volume":"36","author":"Zhu","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2019.10.014_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cca.2014.02.019","article-title":"Improvement of specific detection of circulating tumor cells using combined CD45 staining and fluorescence in situ hybridization","volume":"433","author":"Ning","year":"2014","journal-title":"Clin. Chim. Acta"},{"issue":"9","key":"10.1016\/j.canlet.2019.10.014_bib31","first-page":"9599","article-title":"Detection of circulating tumour cells in patients with epithelial ovarian cancer by a microfluidic system","volume":"10","author":"Rao","year":"2017","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.canlet.2019.10.014_bib32","article-title":"Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin","volume":"7","author":"Po","year":"2018","journal-title":"J. Circ. Biomarkers"},{"issue":"7","key":"10.1016\/j.canlet.2019.10.014_bib33","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.molonc.2016.04.002","article-title":"Gene expression profiling of single circulating tumor cells in ovarian cancer\u2013Establishment of a multi\u2010marker gene panel","volume":"10","author":"Blassl","year":"2016","journal-title":"Mol. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2019.10.014_bib34","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1373\/clinchem.2014.224808","article-title":"ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance","volume":"60","author":"Kuhlmann","year":"2014","journal-title":"Clin. Chem."},{"issue":"5","key":"10.1016\/j.canlet.2019.10.014_bib35","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/IGC.0b013e318216cb91","article-title":"Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy","volume":"21","author":"Aktas","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"30","key":"10.1016\/j.canlet.2019.10.014_bib36","doi-asserted-by":"crossref","first-page":"48820","DOI":"10.18632\/oncotarget.16179","article-title":"EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy","volume":"8","author":"Chebouti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.10.014_bib37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fonc.2013.00044","article-title":"Computational and experimental models of cancer cell response to fluid shear stress","volume":"3","author":"Mitchell","year":"2013","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2407-12-91","article-title":"EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer","volume":"12","author":"Haslehurst","year":"2012","journal-title":"BMC Canc."},{"issue":"5","key":"10.1016\/j.canlet.2019.10.014_bib39","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","article-title":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","volume":"158","author":"Aceto","year":"2014","journal-title":"Cell"},{"issue":"1\u20132","key":"10.1016\/j.canlet.2019.10.014_bib40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cell.2018.11.046","article-title":"Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding","volume":"176","author":"Gkountela","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12272-018-01108-7","article-title":"Therapeutic implications of cancer epithelial-mesenchymal transition (EMT)","volume":"42","author":"Cho","year":"2019","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"4","key":"10.1016\/j.canlet.2019.10.014_bib42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2019.10.014_bib43","doi-asserted-by":"crossref","first-page":"29831","DOI":"10.1038\/srep29831","article-title":"Quantification of somatic chromosomal rearrangements in circulating cell-free DNA from ovarian cancers","volume":"6","author":"Harris","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.canlet.2019.10.014_bib44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/172460080001500204","article-title":"Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer","volume":"15","author":"\u010colakovi\u0107","year":"2000","journal-title":"Int. J. Biol. Mark."},{"issue":"7353","key":"10.1016\/j.canlet.2019.10.014_bib45","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Network","year":"2011","journal-title":"Nature"},{"issue":"136","key":"10.1016\/j.canlet.2019.10.014_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003726","article-title":"Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA","volume":"4","author":"Forshew","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.canlet.2019.10.014_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145754","article-title":"Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers","volume":"10","author":"Pereira","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.canlet.2019.10.014_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002198","article-title":"Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study","volume":"13","author":"Parkinson","year":"2016","journal-title":"PLoS Med."},{"issue":"3","key":"10.1016\/j.canlet.2019.10.014_bib49","doi-asserted-by":"crossref","first-page":"328","DOI":"10.5468\/ogs.2018.61.3.328","article-title":"Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer","volume":"61","author":"Park","year":"2018","journal-title":"Obstet. Gynecol. Sci."},{"issue":"21","key":"10.1016\/j.canlet.2019.10.014_bib50","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","article-title":"Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer","volume":"23","author":"Weigelt","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.10.014_bib51","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1541-7786.MCR-17-0594","article-title":"Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma","volume":"16","author":"Arend","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2019.10.014_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00343","article-title":"Prospective longitudinal ctDNA workflow reveals clinically actionable alterations in ovarian cancer","volume":"3","author":"Oikkonen","year":"2019","journal-title":"JCO Precis. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib53","doi-asserted-by":"crossref","first-page":"10426","DOI":"10.1038\/s41598-019-47030-w","article-title":"Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing","volume":"9","author":"Iwahashi","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.canlet.2019.10.014_bib54","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mgg3.414","article-title":"Next\u2010generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug\u2010resistant recurrent ovarian cancer","volume":"6","author":"Du","year":"2018","journal-title":"Mol. Genet. Genom. Med."},{"key":"10.1016\/j.canlet.2019.10.014_bib55","series-title":"Feasibility of Monitoring Response to the PARP Inhibitor Rucaparib with Targeted Deep Sequencing of Circulating Tumor DNA (ctDNA) in Women with High-Grade Serous Carcinoma on the ARIEL2 Trial","author":"Piskorz","year":"2016"},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib56","doi-asserted-by":"crossref","first-page":"W28","DOI":"10.1593\/neo.131900","article-title":"Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA","volume":"16","author":"Martignetti","year":"2014","journal-title":"Neoplasia"},{"issue":"9","key":"10.1016\/j.canlet.2019.10.014_bib57","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1158\/1078-0432.CCR-16-1078","article-title":"Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses","volume":"23","author":"Vanderstichele","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib58","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12916-016-0667-6","article-title":"Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening","volume":"14","author":"Cohen","year":"2016","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib59","doi-asserted-by":"crossref","first-page":"11205","DOI":"10.1038\/s41598-018-29381-y","article-title":"Massively parallel sequencing of cell-free DNA in plasma for detecting gynaecological tumour-associated copy number alteration","volume":"8","author":"Nakabayashi","year":"2018","journal-title":"Sci. Rep."},{"issue":"60","key":"10.1016\/j.canlet.2019.10.014_bib60","doi-asserted-by":"crossref","first-page":"101325","DOI":"10.18632\/oncotarget.20722","article-title":"Detection of BRCA1\/2 mutations in circulating tumor DNA from patients with ovarian cancer","volume":"8","author":"Ratajska","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.canlet.2019.10.014_bib61","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.canlet.2019.10.014_bib62","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ygyno.2018.05.026","article-title":"ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer","volume":"150","author":"Giannopoulou","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib63","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13073-017-0500-7","article-title":"The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer","volume":"9","author":"Widschwendter","year":"2017","journal-title":"Genome Med."},{"issue":"13","key":"10.1016\/j.canlet.2019.10.014_bib64","doi-asserted-by":"crossref","first-page":"21429","DOI":"10.18632\/oncotarget.15249","article-title":"RASSF1A promoter methylation in high-grade serous ovarian cancer: a direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA","volume":"8","author":"Giannopoulou","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib65","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3892\/ol.2017.6111","article-title":"Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer","volume":"14","author":"Wang","year":"2017","journal-title":"Oncol. Lett."},{"issue":"7","key":"10.1016\/j.canlet.2019.10.014_bib66","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.7314\/APJCP.2015.16.7.3003","article-title":"Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer","volume":"16","author":"Wang","year":"2015","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"3","key":"10.1016\/j.canlet.2019.10.014_bib67","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.7314\/APJCP.2014.15.3.1171","article-title":"Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer","volume":"15","author":"Wu","year":"2014","journal-title":"Asian Pac. J. Cancer Prev. APJCP: Asian Pac. J. Cancer Prev. APJCP"},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib68","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2013.04.048","article-title":"A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA","volume":"130","author":"Zhang","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2019.10.014_bib69","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/147323001204000231","article-title":"Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer","volume":"40","author":"Dong","year":"2012","journal-title":"J. Int. Med. Res."},{"issue":"3","key":"10.1016\/j.canlet.2019.10.014_bib70","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ygyno.2011.08.029","article-title":"Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer","volume":"123","author":"BonDurant","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib71","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2010.09.019","article-title":"Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors","volume":"120","author":"Liggett","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"43","key":"10.1016\/j.canlet.2019.10.014_bib72","doi-asserted-by":"crossref","first-page":"75742","DOI":"10.18632\/oncotarget.20608","article-title":"Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.canlet.2019.10.014_bib73","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/1878-0261.12391","article-title":"Locus\u2010specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma","volume":"13","author":"Calapre","year":"2019","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib74","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/1471-2407-12-325","article-title":"LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival","volume":"12","author":"Kuhlmann","year":"2012","journal-title":"BMC Canc."},{"issue":"7447","key":"10.1016\/j.canlet.2019.10.014_bib75","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature12065","article-title":"Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA","volume":"497","author":"Murtaza","year":"2013","journal-title":"Nature"},{"issue":"6378","key":"10.1016\/j.canlet.2019.10.014_bib76","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"issue":"403","key":"10.1016\/j.canlet.2019.10.014_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"224","key":"10.1016\/j.canlet.2019.10.014_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early-and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.canlet.2019.10.014_bib79","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.2016.70.4627","article-title":"Reversion of BRCA1\/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer","volume":"35","author":"Christie","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2019.10.014_bib80","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e32","article-title":"Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma","volume":"30","author":"Kim","year":"2018","journal-title":"J. Gynecol. Oncol."},{"issue":"16","key":"10.1016\/j.canlet.2019.10.014_bib81","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2019.10.014_bib82","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/IGC.0000000000001190","article-title":"Applying precision medicine to ovarian cancer: proof-of-principle for a \u201cmolecular second look\u201d","volume":"28","author":"Schwartz","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2019.10.014_bib83","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.prp.2018.10.028","article-title":"Peritoneal washing is an adequate source for somatic BRCA1\/2 mutation testing in ovarian malignancies","volume":"215","author":"Barqu\u00edn","year":"2019","journal-title":"Pathol. Res. Pract."},{"issue":"36","key":"10.1016\/j.canlet.2019.10.014_bib84","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2015.61.3083","article-title":"Lavage of the uterine cavity for molecular detection of M\u00fcllerian duct carcinomas: a proof-of-concept study","volume":"33","author":"Maritschnegg","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2019.10.014_bib85","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.3892\/or.2015.3937","article-title":"Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma","volume":"33","author":"Zhou","year":"2015","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.canlet.2019.10.014_bib86","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s12253-015-9914-y","article-title":"Evaluation of cell-free urine microRNAs expression for the use in diagnosis of ovarian and endometrial cancers. A pilot study","volume":"21","author":"Z\u00e1vesk\u00fd","year":"2015","journal-title":"Pathol. Oncol. Res."},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib87","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13048-018-0391-2","article-title":"Comparison of benign peritoneal fluid-and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers","volume":"11","author":"Yamamoto","year":"2018","journal-title":"J. Ovarian Res."},{"issue":"433","key":"10.1016\/j.canlet.2019.10.014_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap8793","article-title":"Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers","volume":"10","author":"Wang","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib89","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12916-018-1157-9","article-title":"Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection","volume":"16","author":"Fiala","year":"2018","journal-title":"BMC Med."},{"key":"10.1016\/j.canlet.2019.10.014_bib90","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/bs.acr.2018.12.003","article-title":"Clonal hematopoiesis: pre-cancer PLUS","volume":"141","author":"Silver","year":"2019","journal-title":"Adv. Cancer Res."},{"issue":"12","key":"10.1016\/j.canlet.2019.10.014_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002206","article-title":"Genomic analysis of uterine lavage fluid detects early endometrial cancers and reveals a prevalent landscape of driver mutations in women without histopathologic evidence of cancer: a prospective cross-sectional study","volume":"13","author":"Nair","year":"2016","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.canlet.2019.10.014_bib92","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.celrep.2019.05.109","article-title":"Ultra-sensitive TP53 sequencing for cancer detection reveals progressive clonal selection in normal tissue over a century of human lifespan","volume":"28","author":"Salk","year":"2019","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.canlet.2019.10.014_bib93","article-title":"Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: the Circulating Cell-Free Genome Atlas (CCGA)","volume":"29","author":"Liu","year":"2018","journal-title":"Ann. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.canlet.2019.10.014_bib94","article-title":"Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance, in ASCO","volume":"37","author":"Liu","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.canlet.2019.10.014_bib95","doi-asserted-by":"crossref","first-page":"15266","DOI":"10.18632\/oncotarget.24555","article-title":"PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma","volume":"9","author":"Morikawa","year":"2018","journal-title":"Oncotarget"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519305117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519305117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:45:01Z","timestamp":1759592701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383519305117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":95,"alternative-id":["S0304383519305117"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2019.10.014","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2019.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}